CEO Todd Harris was paid $5,566,997 in fiscal year 2025, ↓ down 26.5% from fiscal year 2024 (SEC filing 0001193125-26-160360 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$5,566,997 ↓ Todd Harris total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
TYRA's next annual pay disclosure, estimated April 16, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Todd Harris | $658,000 | $0 | $0 | $4,568,037 | $325,710 | $0 | $15,250 | $5,566,997 |
| President, Chief Executive Officer and Director | ||||||||
| Bhavesh Ashar | 45,833 | 0 | 0 | 4,638,420 | 0 | 0 | 1,021 | 4,685,274 |
| Chief Operating Officer | ||||||||
| Douglas Warner | 551,200 | 0 | 0 | 1,607,560 | 198,432 | 0 | 15,051 | 2,372,243 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Todd Harris | $5,566,997 | $7,570,066 | $4,626,119 | ↓ −2,003,069 |
| Bhavesh Ashar | 4,685,274 | — | — | — |
| Douglas Warner | 2,372,243 | 4,725,517 | — | ↓ −2,353,274 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Tyra Biosciences's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper TYRA reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses TYRA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named TYRA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Bhavesh Ashar | COO | $4,685,274 |
| Douglas Warner | Chief Medical Officer | $2,372,243 |
| Todd Harris | CEO | $5,566,997 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Adele M. Gulfo | Independent Director | $553,721 |
| Gilla Kaplan, Ph.D | Former director (through FY2025) | $197,057 |
| Habib J. Dable | Independent Director | — |
| Jake Simson, Ph.D | Independent Director | $203,535 |
| Melissa McCracken, Ph.D | Independent Director | — |
| Nina Kjellson | Former director (through FY2025) | $3,898 |
| Rehan Verjee | Independent Director | $205,570 |
| Robert More | Chair of the Board | $232,670 |
| S. Michael Rothenberg, M.D., Ph.D | Independent Director | $192,465 |
| Susan Moran, M.D., M.S.C.E | Independent Director | $203,272 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Yuliya Rueb | Vice President, Finance (PAO) | 2026-05-05 | A | 28,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Yuliya Rueb | Vice President, Finance (PAO) | 2026-05-05 | A | 8,333 | 0 | 0 | Common | Form 4 ↗ |
| Bhavesh Ashar | Chief Operating Officer | 2026-05-05 | A | 50,295 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bhavesh Ashar | Chief Operating Officer | 2026-05-05 | A | 15,013 | 0 | 0 | Common | Form 4 ↗ |
| Todd Harris | Director | 2026-05-05 | A | 265,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Todd Harris | Director | 2026-05-05 | A | 79,000 | 0 | 0 | Common | Form 4 ↗ |
| Alan Fuhrman | Chief Financial Officer | 2026-05-05 | A | 20,000 | 0 | 0 | Common | Form 4 ↗ |
| Douglas Warner | Chief Medical Officer | 2026-05-05 | A | 85,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alan Fuhrman | Chief Financial Officer | 2026-05-05 | A | 67,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Douglas Warner | Chief Medical Officer | 2026-05-05 | A | 25,000 | 0 | 0 | Common | Form 4 ↗ |
| Rehan Verjee | Director | 2026-05-28 | A | 13,160 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2026-05-28 | A | 13,160 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Michael Rothenberg | Director | 2026-05-28 | A | 13,160 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert More | Director | 2026-05-28 | A | 13,160 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adele M. Gulfo | Director | 2026-05-28 | A | 13,160 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jake Simson | Director | 2026-05-28 | A | 13,160 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Susan Moran | Director | 2026-05-28 | A | 13,160 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rehan Verjee | Director | 2026-09-09 | A | 971.89 | 21 | 20,000 | Common | Form 4 ↗ |
| Yuliya Rueb | Vice President, Finance (PAO) | 2026-09-15 | A | 2,925 | 9 | 26,702 | Common | Form 4 ↗ |
| Todd Harris | Director | 2026-09-15 | A | 864 | 9 | 7,887 | Common | Form 4 ↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2026-09-15 | A | 9,078,529 | 22 | 199,990,915 | Derivative, Class A Common | Form 4 ↗ |
| Alan Fuhrman | Chief Financial Officer | 2026-09-15 | A | 951 | 9 | 8,682 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Todd Harris | OPTION | — | — | — | — | — | $4,568,037 |
| Douglas Warner | OPTION | — | — | — | — | — | 1,607,560 |
| Bhavesh Ashar | OPTION | — | — | — | — | — | 4,638,420 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Todd Harris | $0 | $0 | $4,568,037 | 0.0% |
| Douglas Warner | 0 | 0 | 1,607,560 | 0.0% |
| Bhavesh Ashar | 0 | 0 | 4,638,420 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Douglas Warner | Option | 200,000 | 10.75 | — |
| Todd Harris | Option | 130,625 | 14.35 | — |
| Bhavesh Ashar | Option | 300,000 | 20.81 | — |
| Todd Harris | Option | 522,500 | 10.75 | — |
| Douglas Warner | Option | 178,750 | 21.51 | — |
| Todd Harris | Option | 260,000 | 21.57 | — |
| Todd Harris | Option | 50,625 | 7.14 | — |
The company's compensation program is designed to attract, retain, and motivate talented executives through a combination of fixed base salary, annual performance-based cash bonuses tied to pre-established corporate goals, and equity-based incentive awards that align executive interests with stockholder interests. Base salaries are set at competitive levels reflecting each executive's skill set, experience, role, and responsibilities.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon Rewards Solutions |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-28 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-28 | —a |
a. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Adele M. GulfoIndependent · Compensation | $42,204 | $0 | $421,517 | $0 | $90,000 | $553,721 |
| Robert MoreIndependent · Board Chair · Audit · Nominating and Corporate Governance (Chair) | 86,683 | 0 | 145,987 | 0 | — | 232,670 |
| Rehan VerjeeIndependent · Audit (Chair) · Compensation | 59,583 | 0 | 145,987 | 0 | — | 205,570 |
| Jake Simson, Ph.DIndependent · Nominating and Corporate Governance · Science and Technology (Chair) | 57,548 | 0 | 145,987 | 0 | — | 203,535 |
| Susan Moran, M.D., M.S.C.EIndependent · Compensation (Chair) · Science and Technology | 57,285 | 0 | 145,987 | 0 | — | 203,272 |
| Gilla Kaplan, Ph.DIndependent · Nominating and Corporate Governance · Science and Technology · Not standing for re-election · Departed during FY | 51,070 | 0 | 145,987 | 0 | — | 197,057 |
| S. Michael Rothenberg, M.D., Ph.DIndependent · Science and Technology | 46,478 | 0 | 145,987 | 0 | — | 192,465 |
| Nina KjellsonIndependent · Departed during FY | 3,898 | 0 | — | 0 | — | 3,898 |
| Melissa McCracken, Ph.DIndependent · Audit · Science and Technology | 0 | 0 | 0 | 0 | 0 | 0 |
| Todd Harris, Ph.DEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Habib J. DableIndependent · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $145,987 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 15,000 / 15,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $404,749 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $90,000 |
| Total cost of the board | $494,749 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Tyra Biosciences | 2025 | Todd Harris | $658,000 | $0 | $4,568,037 | $325,710 | $5,566,997 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Todd Harris | DEF 14A | 2026-04-17 | 0001193125-26-160360 | Section “2025 Summary Compensation Table”. As printed: 5,566,997. Filing ↗machine: r2 · c23 · span 216822–216831 |
| 2 | Section 01, Bhavesh Ashar | DEF 14A | 2026-04-17 | 0001193125-26-160360 | Section “2025 Summary Compensation Table”. As printed: 4,685,274. Filing ↗machine: r6 · c23 · span 224363–224372 |
| 3 | Section 01, Douglas Warner | DEF 14A | 2026-04-17 | 0001193125-26-160360 | Section “2025 Summary Compensation Table”. As printed: 2,372,243. Filing ↗machine: r4 · c23 · span 220593–220602 |
| 4 | Section 03, Todd Harris OPTION | DEF 14A | 2026-04-17 | 0001193125-26-160360 | Section “CLASSDIRECTORS&” · grants of plan-based awards table. Filing ↗machine: t67 · r2 · c11 · span 216026–216035 |
| 5 | Section 03, Douglas Warner OPTION | DEF 14A | 2026-04-17 | 0001193125-26-160360 | Section “CLASSDIRECTORS&” · grants of plan-based awards table. Filing ↗machine: t67 · r4 · c11 · span 219797–219806 |
| 6 | Section 03, Bhavesh Ashar OPTION | DEF 14A | 2026-04-17 | 0001193125-26-160360 | Section “CLASSDIRECTORS&” · grants of plan-based awards table. Filing ↗machine: t67 · r6 · c11 · span 223561–223570 |
| 7 | Section 07, pay ratio | 10-K | 2026-03-02 | 0001193125-26-085490 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 8 | Section 08, Adele M. Gulfo | DEF 14A | 2026-04-17 | 0001193125-26-160360 | Section “Director Compensation”. As printed: 553,721. Filing ↗machine: t84 · r2 · c19 · span 305805–305812 |
| 9 | Section 08, Robert More | DEF 14A | 2026-04-17 | 0001193125-26-160360 | Section “Director Compensation”. As printed: 232,670. Filing ↗machine: t84 · r7 · c19 · span 313988–313995 |
| 10 | Section 08, Rehan Verjee | DEF 14A | 2026-04-17 | 0001193125-26-160360 | Section “Director Compensation”. As printed: 205,570. Filing ↗machine: t84 · r10 · c19 · span 318905–318912 |
| 11 | Section 08, Jake Simson, Ph.D | DEF 14A | 2026-04-17 | 0001193125-26-160360 | Section “Director Compensation”. As printed: 203,535. Filing ↗machine: t84 · r9 · c19 · span 317267–317274 |
| 12 | Section 08, Susan Moran, M.D., M.S.C.E | DEF 14A | 2026-04-17 | 0001193125-26-160360 | Section “Director Compensation”. As printed: 203,272. Filing ↗machine: t84 · r6 · c19 · span 312376–312383 |
| 13 | Section 08, Gilla Kaplan, Ph.D | DEF 14A | 2026-04-17 | 0001193125-26-160360 | Section “Director Compensation”. As printed: 197,057. Filing ↗machine: t84 · r3 · c19 · span 307425–307432 |
| 14 | Section 08, S. Michael Rothenberg, M.D., Ph.D | DEF 14A | 2026-04-17 | 0001193125-26-160360 | Section “Director Compensation”. As printed: 192,465. Filing ↗machine: t84 · r8 · c19 · span 315648–315655 |
| 15 | Section 08, Nina Kjellson | DEF 14A | 2026-04-17 | 0001193125-26-160360 | Section “Director Compensation”. As printed: 3,898. Filing ↗machine: t84 · r4 · c3 · span 307995–308000 |
| 16 | Section 08, Melissa McCracken, Ph.D | DEF 14A | 2026-04-17 | 0001193125-26-160360 | Section “Director Compensation”. As printed: 0. Filing ↗machine: t84 · r5 · c19 · span 310716–310723 |
| 17 | Section 08, Todd Harris, Ph.D | DEF 14A | 2026-04-17 | 0001193125-26-160360 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 18 | Section 08, Habib J. Dable | DEF 14A | 2026-04-17 | 0001193125-26-160360 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 19 | Section 02, Yuliya Rueb 2026-05-05 | Form 4 | 2026-05-07 | 0001193125-26-212111 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Yuliya Rueb 2026-05-05 | Form 4 | 2026-05-07 | 0001193125-26-212111 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Bhavesh Ashar 2026-05-05 | Form 4 | 2026-05-07 | 0001193125-26-212112 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Bhavesh Ashar 2026-05-05 | Form 4 | 2026-05-07 | 0001193125-26-212112 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Todd Harris 2026-05-05 | Form 4 | 2026-05-07 | 0001193125-26-212114 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Todd Harris 2026-05-05 | Form 4 | 2026-05-07 | 0001193125-26-212114 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Alan Fuhrman 2026-05-05 | Form 4 | 2026-05-07 | 0001193125-26-212115 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Douglas Warner 2026-05-05 | Form 4 | 2026-05-07 | 0001193125-26-212116 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Alan Fuhrman 2026-05-05 | Form 4 | 2026-05-07 | 0001193125-26-212115 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Douglas Warner 2026-05-05 | Form 4 | 2026-05-07 | 0001193125-26-212116 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Rehan Verjee 2026-05-28 | Form 4 | 2026-06-01 | 0001193125-26-251539 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, RA CAPITAL MANAGEMENT, L.P. 2026-05-28 | Form 4 | 2026-06-01 | 0001231919-26-000590 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Stephen Michael Rothenberg 2026-05-28 | Form 4 | 2026-06-01 | 0001193125-26-251532 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Robert More 2026-05-28 | Form 4 | 2026-06-01 | 0001193125-26-251534 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Adele M. Gulfo 2026-05-28 | Form 4 | 2026-06-01 | 0001193125-26-251536 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Jake Simson 2026-05-28 | Form 4 | 2026-06-01 | 0001193125-26-251537 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Susan Moran 2026-05-28 | Form 4 | 2026-06-01 | 0001193125-26-251538 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Rehan Verjee 2026-09-09 | Form 4 | 2026-09-11 | 0001193125-26-389333 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Yuliya Rueb 2026-09-15 | Form 4 | 2026-09-17 | 0001193125-26-394734 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Todd Harris 2026-09-15 | Form 4 | 2026-09-17 | 0001193125-26-394738 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, RA CAPITAL MANAGEMENT, L.P. 2026-09-15 | Form 4 | 2026-09-17 | 0001231919-26-001194 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Alan Fuhrman 2026-09-15 | Form 4 | 2026-09-17 | 0001193125-26-394731 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 06, 2026 vote | Form 8-K | 2026-04-17 | 0001193125-26-160360 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 42 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 43 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 44 | Section 09b board cost (computed) | Computed | — | — | Cash 404,749 + equity 0 + all other 90,000 = 494,749, summed across the director compensation table rows.machine: formula: Σ = 494,749 |
| 45 | Tyra Biosciences (subject), Section 10b CEO total | DEF 14A | 2026-04-17 | 0001193125-26-160360 | CEO total compensation as printed in Tyra Biosciences's own proxy. As printed: 5,566,997. Filing ↗machine: r2 · c23 · span 216822–216831 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.